Monopar Therapeutics, Inc. (MNPR)

NASDAQ: MNPR · IEX Real-Time Price · USD
2.02
-0.26 (-11.40%)
Jun 24, 2022 3:59 PM EDT - Market closed
-11.40%
Market Cap 25.49M
Revenue (ttm) n/a
Net Income (ttm) -9.68M
Shares Out 12.62M
EPS (ttm) -0.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16,853
Open 2.19
Previous Close 2.28
Day's Range 2.02 - 2.34
52-Week Range 1.70 - 6.98
Beta 0.77
Analysts Buy
Price Target 26.11 (+1,192.6%)
Earnings Date Aug 11, 2022

About MNPR

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft... [Read more...]

Industry Biotechnology
IPO Date Dec 19, 2019
Employees 9
Stock Exchange NASDAQ
Ticker Symbol MNPR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for MNPR stock is "Buy." The 12-month stock price forecast is 26.11, which is an increase of 1,192.57% from the latest price.

Price Target
$26.11
(1,192.57% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments

Validive ® Phase 2b/3 VOICE Trial Continues Enrolling Patients Toward Interim Camsirubicin Phase 1b Dose-Escalation Trial Clears 3 rd Dose Level, Now Enrolling 4 th

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments

Validive ® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe

Monopar to Present at the 34th Annual Roth Conference and Maxim's 2022 Virtual Growth Conference

WILMETTE, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend ...

Monopar Announces Clinical and Preclinical Program Updates

WILMETTE, Ill., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend l...

Monopar to Present at the H.C. Wainwright BioConnect Conference

WILMETTE, Ill., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend l...

Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial

WILMETTE, Ill., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend l...

Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments

First Patients Dosed in Camsirubicin Phase 1b Clinical Trial in U.S. Validive ® Phase 2b/3 VOICE Trial Cleared to Enroll in Europe and on Track for Reaching Interim in H1 2022

Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Ti...

WILMETTE, Ill., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend l...

Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sa...

WILMETTE, Ill., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend ...

Monopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates

Camsirubicin Phase 1b Clinical Trial Anticipated to Start in the U.S. in Q4 2021 Validive ® Phase 2b/3 VOICE Trial on Track for Reaching Interim Analysis in H1 2022

Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial

WILMETTE, Ill., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed t...

Monopar Stock Gains On Launch Of Early Stage Soft Tissue Cancer Trial With Camsirubicin

The FDA has signed off Monopar Therapeutics Inc's (NASDAQ: MNPR) IND to commence an open-label Phase 1b dose-escalation trial to evaluate camsirubicin plus pegfilgrastim in patients with advanced soft t...

Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma

WILMETTE, Ill., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed t...

Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MAS...

WILMETTE, Ill., June 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed t...

Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University ...

Development of novel Camsirubicin analog expands Monopar's therapeutic pipeline Development of novel Camsirubicin analog expands Monopar's therapeutic pipeline

Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates

First Patient Dosed in Validive ® Phase 2b/3 VOICE Clinical Trial Camsirubicin Run-in Clinical Trial Now Planned to Start in 2H 2021 Potential Utility Reported for MNPR-101 as Imaging Agent in Cancer Su...

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes announced a corporate update describing progress in its key programs during the past year and upcoming milestones.

Monopar Therapeutics Is Trading Higher On Announcing Its uPA Radiotracer Along With Pet Imaging Can Detect Breast Cancer

Monopar Therapeutics Inc (NASDAQ: MNPR) has announced the publication of a peer-reviewed study that demonstrated Monopar's Urokinase plasminogen activator (uPA) antibody fragment radiotracer could poten...

Monopar's uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study

WILMETTE, Ill., March 30, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed ...

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Updates

Validive ® Phase 2b/3 VOICE Clinical Trial Commenced Camsirubicin Phase 2 Clinical Trial Anticipated to Start in Q2 2021 MNPR-101-Conjugate Data Published in European Journal of Cancer

Monopar Partners with Seasoned Medtech Executive to Explore the Potential of MNPR-101 as a uPAR Imaging Agent in Canc...

- Initial focus on use in bladder cancer surgery - Initial focus on use in bladder cancer surgery

Monopar Therapeutics to Present at Upcoming Investor Conferences

WILMETTE, Ill., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed t...

Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemor...

There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM

Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Out...

WILMETTE, Ill., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed t...

Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada

WILMETTE, Ill., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed t...